People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

36.85USD
26 Dec 2014
Price Change (% chg)

$0.88 (+2.45%)
Prev Close
$35.97
Open
$35.99
Day's High
$37.43
Day's Low
$35.75
Volume
20,356
Avg. Vol
87,441
52-wk High
$40.00
52-wk Low
$12.66

Search Stocks

Summary

Name Age Since Current Position

Roger Newton

63 Executive Chairman of the Board, Chief Scientific Officer

Timothy Mayleben

53 2004 President, Chief Executive Officer

Narendra Lalwani

61 2014 Chief Operating Officer, Executive Vice President - Research & Development

Antonio Gotto

78 2014 Director

Mark McGovern

61 2014 Director

Gilbert Omenn

71 2014 Director

Nicole Vitullo

54 Director

Biographies

Name Description

Roger Newton

Dr. Roger S. Newton serves as Executive Chairman of the Board of Directors and Chief Scientific Officer at Esperion Therapeutics Inc. From August 1981 until May 1998, Dr. Newton was employed at Parke-Davis Pharmaceutical Research, Warner-Lambert Company, a publicly-held company, including as a Distinguished Research Fellow in Vascular and Cardiac Diseases, and where he was also the co-discoverer, chairman of the discovery team and member of the development team for the drug atorvastatin (Lipitor®). Dr. Newton received an A.B. in Biology from Lafayette College, an M.S. in Nutritional Biochemistry from the University of Connecticut and a Ph.D. in Nutrition from the University of California, Davis. Dr. Newton specialized in atherosclerosis research during a post-doctoral fellowship at the University of California, San Diego. He currently holds a faculty appointment as an adjunct associate professor in the Department of Pharmacology at the University of Michigan Medical School. Since 2001, Dr. Newton has been a member of the Board of Directors of Rubicon Genomics, Inc., a privately-held company. He is a member of the steering committee of the Michigan Life Sciences Corridor and was formerly the Executive Director of Great Lakes Venture Quest.

Timothy Mayleben

Mr. Timothy M. Mayleben has served as Chief Executive Officer and President at Esperion Therapeutics Inc., since February 2004. Mr. Mayleben served as Senior Vice President, Operations and Finance from January 2002 until April 2002, after serving as Vice President, Finance from January 1999 until January 2002. Mr. Mayleben has more than 16 years experience working with high-growth technology companies. Prior to joining Esperion, Mr. Mayleben served as a Director of Business Development for Engineering Animation, Inc., a publicly-held company, from September 1998 to December 1998. From July 1997 to September 1998, Mr. Mayleben served as Chief Operating Officer and Chief Financial Officer of Transom Technologies, Inc., a privately-held company that was acquired by Engineering Animation, Inc. From September 1990 to July 1997, Mr. Mayleben served in various managerial positions, including as Director of Operations of Applied Intelligent Systems, Inc., a privately-held company. Prior to that, Mr. Mayleben was a manager with the Enterprise Group of Arthur Andersen & Co. Mr. Mayleben received a B.B.A. from the University of Michigan and an M.B.A. from the Northwestern University Kellogg Graduate School of Management. Mr. Mayleben was formerly a member of the Board of Directors of Computer Challenge Inc., a non-profit corporation.

Narendra Lalwani

Dr. Narendra D. Lalwani, Ph.D., is appointed as Chief Operating Officer, Executive Vice President - Research & Development of Esperion Therapeutics, Inc., effective August 1, 2014. Dr. Lalwani served as Chief Scientific Officer at Cerenis Therapeutics from June 2007 to January 2014, and as Senior Director, Drug Safety Research and Development at Pfizer, Inc., from February 2004 to June 2007. Previously, Dr. Lalwani was Vice President of Drug Safety Evaluation and a member of the executive leadership team in the prior Esperion Therapeutics, Inc., from its inception in 1998 until its acquisition by Pfizer in 2004, and worked in the Department of Pathology and Experimental Toxicology at Parke-Davis Pharmaceutical Research, Warner-Lambert from 1990 to 1997. Dr. Lalwani holds a M.S. and a Ph.D. in Biophysics from the University of Bombay, a BS in Microbiology and Chemistry from Gujarat University, and a MBA from the Ross School of Business, University of Michigan. He is Diplomate of the American Board of Toxicology and also a Fellow of the American Heart Association.

Antonio Gotto

Dr. Antonio M. Gotto, Jr., M.D., D. Phil, is Director of the Esperion Therapeutics Inc. Dr. Gotto currently serves as Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, Dr. Gotto served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Dr. Gotto served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Dr. Gotto currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. Dr. Gotto is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Dr. Gotto holds a B.A. degree from Vanderbilt University, a D.Phil. degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an M.D. degree from Vanderbilt University School of Medicine. Dr. Gotto completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. Dr. Gotto is also a member of the Board of Directors of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). The Company believes that Dr. Gotto is qualified to serve as a director based on his broad experience in the industry in which it operates.

Mark McGovern

Dr. Mark E. McGovern, M.D., FACC, FACP is a Director of Esperion Therapeutics Inc. Dr. McGovern is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies. His experience includes 11 years at Bristol-Myers Squibb, where Dr. McGovern was responsible for the clinical development of pravastatin (Pravachol®), in particular the programs for atherosclerosis regression and coronary heart disease prevention, including the WOSCOPS (West of Scotland Coronary Prevention Study), CARE (Cholesterol and Recurrent Events), and LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trials. He subsequently spent 10 years at Kos Pharmaceuticals, where he last served as executive vice president, medical affairs, and chief medical officer. During his career at Kos, Dr. McGovern oversaw the phase IV trials of extended-release niacin (Niaspan®), and the registration programs for the first combination lipid therapies, niacin extended-release/lovastatin (Advicor®) and niacin extended release/simvastatin (Simcor®). Dr. McGovern currently serves as a consultant to the pharmaceutical industry for cardiovascular and atherosclerosis drug development. He earned his bachelor's degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Dr. McGovern is a Fellow of the American College of Cardiology and the American College of Physicians. He has published extensively on lipid management and its role in the treatment of coronary heart disease.

Gilbert Omenn

Dr. Gilbert S. Omenn, M.D., Ph.D., is Director of the Company. Dr. Omenn is currently Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health at the University of Michigan, a position he has held since 1997. Since 2005 he has been Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. From 1997 to 2002, Dr. Omenn served as Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs. Previously, Dr. Omenn was Professor of Medicine and of Environmental Health, and Dean of the School of Public Health and Community Medicine, at the University of Washington. Dr. Omenn was a member of the intramural program of National Institutes of Health (“NIH”) in the Anfinsen Lab and was a Howard Hughes Investigator with NIH grants spanning four decades. He currently serves on the Scientific Management Review Board of the NIH and the Community Preventive Services Task Force of the Center for Disease Control (“CDC”). He served previously on the National Cancer Advisory Board, National Heart, Lung, and Blood Institute Advisory Council, the Society of Fellows for the NIH National Center for Minority Health and Health Disparities, and the Director’s Advisory Committee for the CDC. Dr. Omenn was a director of Amgen Inc. (NASDAQ: AMGN) from January 1987 to May 2014, serving on the Audit, Corporate Compliance, and Nominating Committees, and a director of Rohm & Haas Co. (now a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW)), from May 1987 until March 2009, serving on the Audit, Nominating, and Sustainability Committees. Dr. Omenn earned his bachelor’s degree summa cum laude from Princeton University, his medical degree magna cum laude from Harvard Medical School, and his Ph.D. in genetics from the University of Washington.

Nicole Vitullo

Ms. Nicole Vitullo serves as Member of the Board of Directors at Esperion Therapeutics Inc. Apart from that she serves as Director at Domain Associates, LLC. Her present board memberships include, Achillion Pharmaceuticals, Celator Pharmaceuticals, Durata Therapeutics, Marinus Pharmaceuticals and VentiRx Pharmaceuticals. Past Board memberships include Calixa Therapeutics, Cerexa, Eunoe and Onyx Pharmaceuticals. In addition to investment responsibilities, she is involved in the distribution/liquidation strategies for the public companies in Domain's Venture Capital portfolios. From 2000 to 2011, Ms. Vitullo was responsible for Domain Public Equity Partners L.P. Ms. Vitullo received her Masters of Business Administration and Bachelors of Arts degrees from the University of Rochester.

Basic Compensation

Name Fiscal Year Total

Roger Newton

1,829,640

Timothy Mayleben

3,450,160

Narendra Lalwani

--

Antonio Gotto

--

Mark McGovern

--

Gilbert Omenn

--

Nicole Vitullo

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Roger Newton

556,437 1,158,823

Timothy Mayleben

405,468 1,090,751

Narendra Lalwani

0 0

Antonio Gotto

0 0

Mark McGovern

0 0

Gilbert Omenn

0 0

Nicole Vitullo

0 0
Search Stocks